NCT00871559View on ClinicalTrials.gov

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Advanced Solid Malignancies
Interventions
DRUG

REGN421(SAR153192)

Trial Locations (8)

Unknown

Aurora

Indianapolis

Boston

Detroit

St Louis

New York

Columbus

Oklahoma City

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY